偏头痛急性期和预防性治疗进展

doi:10.3969/j.issn.1672-6731.2022.02.007

摘要/Abstract

摘要： 偏头痛是常见的神经系统疾病，其高患病率和所导致的失能加重患者及其家庭和社会疾病负担。然而，目前的偏头痛治疗方案并不能完全满足临床需要且常伴有各种不良反应，因此亟待新的治疗方案。本文综述近年偏头痛急性期和预防性治疗的药物治疗和非药物治疗研究进展。

关键词: 偏头痛, 药物疗法, 血清素受体激动剂, 降钙素基因相关肽, 垂体腺苷酸环化酶激活多肽, 抗体,单克隆, 针刺疗法, 综述

Abstract: Migraine is a common and often disabling neurologic disease, its high prevalence and disability significantly impact on patients and relatives, contributing to heavy social and economic burden. However, currently available migraine treatment options are limited and are often associated with many intolerable side-effects. Therefore, it is necessary to explore new therapeutic options for migraine. This review discusses the most recent and evidence-based advances in pharmacological and non-pharmacological treatment approaches for migraine.

Key words: Migraine, Drug therapy, Serotonin receptor agonists, Calcitonin gene-related peptide, Pituitary adenylate cyclase-activating polypeptide, Antibodies, monoclonal, Acupuncture therapy, Review

林晓雪, 刘颖元, 张淑华, 董钊. 偏头痛急性期和预防性治疗进展[J]. 中国现代神经疾病杂志, 2022, 22(2): 99-103.

LIN Xiao-xue, LIU Ying-yuan, ZHANG Shu-hua, DONG Zhao. Advances in acute and preventive treatment of migraine[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(2): 99-103.

http://journal11.magtechjournal.com/cjcnn/CN/Y2022/V22/I2/99

参考文献

[1] Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, Fang Y, Cao X, He M, Steiner T. The prevalence and burden of primary headaches in China:a population-based door-to-door survey[J]. Headache, 2012, 52:582-591.
[2] GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2018, 17:954-976.
[3] Wöber C, Wöber-Bingöl Ç, Uluduz D, Aslan TS, Uygunoglu U, Tüfekçi A, Alp SI, Duman T, Sürgün F, Emir GK, Demir CF, Balgetir F, Özdemir YB, Auer T, Siva A, Steiner TJ. Undifferentiated headache:broadening the approach to headache in children and adolescents, with supporting evidence from a nationwide school-based cross-sectional survey in Turkey[J]. J Headache Pain, 2018, 19:18.
[4] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390:1211-1259.
[5] Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults:fourth edition[J]. Cephalalgia, 2019, 39:687-710.
[6] Head and Face Pain Group, Pain Branch, Chinese Medical Association; Pain and Sensory Disorders Special Committee, Neurologist Branch, Chinese Medical Doctor Association. Guidelines for prevention and treatment of migraine in China[J]. Zhongguo Teng Tong Yi Xue Za Zhi, 2016, 22:721-727[.中华医学会疼痛学分会头面痛学组, 中国医师协会神经内科医师分会疼痛和感觉障碍专委会. 中国偏头痛防治指南[J]. 中国疼痛医学杂志, 2016, 22:721-727.]
[7] Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults[J]. Cochrane Database Syst Rev, 2013, (4):CD008040.
[8] Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults[J]. Cochrane Database Syst Rev, 2013, (10):CD008039.
[9] Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults[J]. Cochrane Database Syst Rev, 2013, (4):CD008783.
[10] Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action:review of a selective 5-HT(1F) agonist[J]. J Headache Pain, 2020, 21:71.
[11] Ashina M. Migraine[J]. N Engl J Med, 2020, 383:1866-1876.
[12] Diener HC. The risks or lack thereof of migraine treatments in vascular disease[J]. Headache, 2020, 60:649-653.
[13] Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P. Aids to management of headache disorders in primary care (2nd edition):on behalf of the European Headache Federation and Lifting The Burden:the Global Campaign against Headche[J]. J Headache Pain, 2019, 20:57.
[14] Parikh S. Lasmiditan for acute treatment of migraine[J]. Drugs Today (Barc), 2021, 57:89-100.
[15] DeJulio PA, Perese JK, Schuster NM, Oswald JC. Lasmiditan for the acute treatment of migraine[J]. Pain Manag, 2021, 11:437-449.
[16] Mecklenburg J, Raffaelli B, Neeb L, Sanchez Del Rio M, Reuter U. The potential of lasmiditan in migraine[J]. Ther Adv Neurol Disord, 2020, 13:1756286420967847.
[17] Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine:a phase 3 randomised study[J]. Neurology, 2018, 91:e2222-2232.
[18] Rau JC, Navratilova E, Oyarzo J, Johnson KW, Aurora SK, Schwedt TJ, Dodick DW, Porreca F. Evaluation of LY573144(lasmiditan) in a preclinical model of medication overuse headache[J]. Cephalalgia, 2020, 40:903-912.
[19] Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J, Buchanan AS. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine:results from SAMURAI and SPARTAN[J]. Cephalalgia, 2019, 39:957-966.
[20] Negro A, Martelletti P. Novel synthetic treatment options for migraine[J]. Expert Opin Pharmacother, 2021, 22:907-922.
[21] van Hoogstraten WS, MaassenVanDenBrink A. The need for new acutely acting antimigraine drugs:moving safely outside acute medication overuse[J]. J Headache Pain, 2019, 20:54.
[22] Chiang CC, VanderPluym JH. Ubrogepant in the acute management of migraine:a narrative review[J]. J Pain Res, 2021, 14:1185-1192.
[23] Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the treatment of migraine[J]. N Engl J Med, 2019, 381:2230-2241.
[24] Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine:the ACHIEVE Ⅱ randomised clinical trial[J]. JAMA, 2019, 322:1887-1898.
[25] Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine:a randomised, phase 3, double-blind, placebo-controlled trial[J]. Lancet, 2019, 394:737-745.
[26] American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice[J]. Headache, 2019, 59:1-18.
[27] Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, Aube M, Leroux E, Becker WJ; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline:acute drug therapy for migraine headache[J]. Can J Neurol Sci, 2013, 40(5 Suppl 3):1-80.
[28] Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide:a new era in migraine therapy[J]. Lancet, 2019, 394:1765-1774.
[29] Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine:PROMISE-2[J]. Neurology, 2020, 94:e1365-1377.
[30] Chiang CC, Schwedt TJ. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine:the monoclonal antibodies and gepants[J]. Prog Brain Res, 2020, 255:143-170.
[31] Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful:a randomised, double-blind, placebo-controlled, phase 3b study[J]. Lancet, 2018, 392:2280-2287.
[32] Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS):a randomised, double-blind, placebo-controlled, phase 3b trial[J]. Lancet, 2019, 394:1030-1040.
[33] Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK, Terwindt GM, Goadsby PJ. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure:results from two global randomized clinical trials[J]. Eur J Neurol, 2020, 27:609-618.
[34] Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan M, Trugman JM; ADVANCE Study Group. Atogepant for the preventive treatment of migraine[J]. N Engl J Med, 2021, 385:695-706.
[35] Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine:a phase 2/3, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2021, 397:51-60.
[36] Yu S, Ran Y, Xiao W, Tang W, Zhao J, Chen W, Zhuang H, Ouyang C, Lin H, Liu D, Chen T, Huang H, Wang B, Hao Y, Yan Z, Zhao S, Wang Y, Ni J, Wang C, Ding W, Li G, Cao J, Tian S. Treatment of migraines with Tianshu capsule:a multi-center, double-blind, randomized, placebo-controlled clinical trial[J]. BMC Complement Altern Med, 2019, 19:370.
[37] Yu S, Ran Y, Wan Q, Yang X, Chen H, Wang H, Hu X, Mao S, Yu T, Luo G, Gao X, Li X, Zhou M, Li Y. Efficacy and safety of toutongning capsule in patients with migraine:a multicenter, randomized, double-blind, placebo-controlled trial[J]. J Altern Complement Med, 2019, 25:1215-1224.
[38] Reuter U, McClure C, Liebler E, Pozo-Rosich P. Non-invasive neuromodulation for migraine and cluster headache:a systematic review of clinical trials[J]. J Neurol Neurosurg Psychiatry, 2019, 90:796-804.
[39] Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA, Vickers A, White AR. Acupuncture for the prevention of episodic migraine[J]. Cochrane Database Syst Rev, 2016, (6):CD001218.
[40] Zhao L, Chen J, Li Y, Sun X, Chang X, Zheng H, Gong B, Huang Y, Yang M, Wu X, Li X, Liang F. The long-term effect of acupuncture for migraine prophylaxis:a randomized clinical trial[J]. JAMA Intern Med, 2017, 177:508-515.
[41] Xu S, Yu L, Luo X, Wang M, Chen G, Zhang Q, Liu W, Zhou Z, Song J, Jing H, Huang G, Liang F, Wang H, Wang W. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura:multicentre, randomised clinical trial[J]. BMJ, 2020, 368:m697.

选择文件类型/文献管理软件名称

选择包含的内容

2 偏头痛急性期和预防性治疗进展

Advances in acute and preventive treatment of migraine

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[2]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[3]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[4]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[5]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[6]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[7]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[8]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[9]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[10]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[11]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[12]	俞淑凤, 李宁, 徐健, 王鹏. 颈动脉漂浮血栓相关缺血性卒中诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(7): 638-642.
[13]	魏俊吉. 神经外科重症医学规范化诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(6): 477-478.
[14]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.
[15]	曲鑫, 赵浩, 尚峰, 王宁. 神经重症目标温度管理[J]. 中国现代神经疾病杂志, 2023, 23(6): 485-489.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 偏头痛急性期和预防性治疗进展

Advances in acute and preventive treatment of migraine

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价